| Ms Carol A Dovidas, RPH | |
|
7 Stony Hill Rd, Bethel, CT 06801-1030 | |
| (203) 448-1030 | |
| Not Available |
| Full Name | Ms Carol A Dovidas |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 7 Stony Hill Rd, Bethel, Connecticut |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366736639 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 0009358 (Connecticut) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Carol A Dovidas, RPH 7 Stony Hill Rd, Bethel, CT 06801-1030 Ph: (203) 448-1030 | Ms Carol A Dovidas, RPH 7 Stony Hill Rd, Bethel, CT 06801-1030 Ph: (203) 448-1030 |
News Archive
MedQuist Inc., a leading provider of integrated clinical documentation solutions for the U.S. healthcare industry, announced today that it has entered into definitive agreements relating to a $310 million financing consisting of a $225 million senior secured credit facility and the issuance of $85 million of senior subordinated notes.
A new study led by SFU health sciences researchers Prabjit Barn and Ryan Allen reveals fetal growth may improve if pregnant women use portable air purifiers inside their homes.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has held its second meeting with the Australian Therapeutic Goods Administration ("TGA") to discuss milestones for approval of PV-10 for treatment of metastatic melanoma. The TGA is the part of the Australian Government's Department of Health and Ageing responsible for the assessment, approval and monitoring of therapeutic goods available in Australia. The initial meeting with the TGA was held in October 2008.
NewLink Genetics Corporation announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for a pivotal Phase 3 trial of its HyperAcute immunotherapy in pancreatic cancer. Pancreatic cancer is highly lethal and is currently an area of very significant unmet medical need. The SPA is a written agreement between NewLink as the trial sponsor and the FDA regarding the design, endpoints, and planned statistical analysis of a Phase 3 trial to be used in support of a Biologic License Application (BLA).
› Verified 6 days ago
Debbie A Dombrowski, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 7 Durant Ave, Bethel, CT 06801 Phone: 203-794-9500 | |
Patryk Stryjewski, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1 Roberts Dr, Bethel, CT 06801 Phone: 203-461-4562 | |
Dr. Randy David Miller, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 7 Stony Hill Rd, Bethel, CT 06801 Phone: 203-448-1030 | |
Nadia Jabbar, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 7 Durant Ave, Bethel, CT 06801 Phone: 203-794-9500 | |
Mehak Talwar, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 289 Greenwood Ave, Bethel, CT 06801 Phone: 203-792-6190 | |
Susan Montuori, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 7 Durant Ave, Bethel, CT 06801 Phone: 203-794-9500 Fax: 203-795-1005 | |
Dr. Rosalba Gugliotti, PHARM.D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 7 Stony Hill Rd, Bethel, CT 06801 Phone: 203-448-1030 |